FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313339962> ?p ?o ?g. }

• W4313339962 endingPage "163" @default.
• W4313339962 startingPage "157" @default.
• W4313339962 abstract "Purpose To investigate the relationship of anti-vascular endothelial growth factor (anti-VEGF) treatment discontinuation with baseline factors and outcomes in eyes treated initially with aflibercept or bevacizumab for macular edema from central or hemiretinal vein occlusion. Design Long-term follow-up after a randomized clinical trial from 64 US centers. Methods Analysis included 150 SCORE2 Month 60 completers classified into 3 groups: discontinued treatment early, treated intermittently, and treated continuously. Outcomes included visual acuity (VA) and central subfield thickness (CST). Results Patients who discontinued treatment early were younger (60.9 years, vs 66.7 and 70.5 for the treated intermittently and treated continuously groups; P = .001), and 17.4% were Black, compared to 19.5% and 4.7% for the treated intermittently and treated continuously groups (P = .006). At Month 60, the discontinued treatment early group had a higher proportion with complete resolution of macular edema (69.6%) than those treated intermittently (15.0%) and treated continuously (15.7%) (P < .001). Least-squares means analyses over follow-up demonstrated that the discontinued treatment early group had a lower mean CST (257 µm) than the treated intermittently (CST = 303 µm, P = .02) and treated continuously (CST = 300 µm, P = .01) groups. Conclusions Compared to those treated continuously, those who discontinued treatment early were younger and more likely Black. The discontinued treatment early group had a higher proportion with complete resolution of macular edema at Month 60, and a lower mean CST over follow-up, but not better VA, than the treated continuously and treated intermittently groups. Results support the need for continued monitoring and individualized treatment for patients treated with anti-VEGF for macular edema from central or hemiretinal vein occlusion. To investigate the relationship of anti-vascular endothelial growth factor (anti-VEGF) treatment discontinuation with baseline factors and outcomes in eyes treated initially with aflibercept or bevacizumab for macular edema from central or hemiretinal vein occlusion. Long-term follow-up after a randomized clinical trial from 64 US centers. Analysis included 150 SCORE2 Month 60 completers classified into 3 groups: discontinued treatment early, treated intermittently, and treated continuously. Outcomes included visual acuity (VA) and central subfield thickness (CST). Patients who discontinued treatment early were younger (60.9 years, vs 66.7 and 70.5 for the treated intermittently and treated continuously groups; P = .001), and 17.4% were Black, compared to 19.5% and 4.7% for the treated intermittently and treated continuously groups (P = .006). At Month 60, the discontinued treatment early group had a higher proportion with complete resolution of macular edema (69.6%) than those treated intermittently (15.0%) and treated continuously (15.7%) (P < .001). Least-squares means analyses over follow-up demonstrated that the discontinued treatment early group had a lower mean CST (257 µm) than the treated intermittently (CST = 303 µm, P = .02) and treated continuously (CST = 300 µm, P = .01) groups. Compared to those treated continuously, those who discontinued treatment early were younger and more likely Black. The discontinued treatment early group had a higher proportion with complete resolution of macular edema at Month 60, and a lower mean CST over follow-up, but not better VA, than the treated continuously and treated intermittently groups. Results support the need for continued monitoring and individualized treatment for patients treated with anti-VEGF for macular edema from central or hemiretinal vein occlusion." @default.
• W4313339962 created "2023-01-06" @default.
• W4313339962 creator A5002283547 @default.
• W4313339962 creator A5017043678 @default.
• W4313339962 creator A5051310627 @default.
• W4313339962 creator A5077460225 @default.
• W4313339962 creator A5086984489 @default.
• W4313339962 date "2023-04-01" @default.
• W4313339962 modified "2023-09-29" @default.
• W4313339962 title "SCORE2 Report 20: Relationship of Treatment Discontinuation With Visual Acuity and Central Subfield Thickness Outcomes" @default.
• W4313339962 cites W1898187276 @default.
• W4313339962 cites W2143845230 @default.
• W4313339962 cites W2553351963 @default.
• W4313339962 cites W2612836720 @default.
• W4313339962 cites W2613397178 @default.
• W4313339962 cites W2979643225 @default.
• W4313339962 cites W4224289554 @default.
• W4313339962 cites W4292528167 @default.
• W4313339962 doi "https://doi.org/10.1016/j.ajo.2022.12.026" @default.
• W4313339962 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36584835" @default.
• W4313339962 hasPublicationYear "2023" @default.
• W4313339962 type Work @default.
• W4313339962 citedByCount "0" @default.
• W4313339962 crossrefType "journal-article" @default.
• W4313339962 hasAuthorship W4313339962A5002283547 @default.
• W4313339962 hasAuthorship W4313339962A5017043678 @default.
• W4313339962 hasAuthorship W4313339962A5051310627 @default.
• W4313339962 hasAuthorship W4313339962A5077460225 @default.
• W4313339962 hasAuthorship W4313339962A5086984489 @default.
• W4313339962 hasConcept C118487528 @default.
• W4313339962 hasConcept C141071460 @default.
• W4313339962 hasConcept C168563851 @default.
• W4313339962 hasConcept C2776694085 @default.
• W4313339962 hasConcept C2777802072 @default.
• W4313339962 hasConcept C2778257484 @default.
• W4313339962 hasConcept C2778715236 @default.
• W4313339962 hasConcept C2778749236 @default.
• W4313339962 hasConcept C2780347916 @default.
• W4313339962 hasConcept C2780886150 @default.
• W4313339962 hasConcept C71924100 @default.
• W4313339962 hasConceptScore W4313339962C118487528 @default.
• W4313339962 hasConceptScore W4313339962C141071460 @default.
• W4313339962 hasConceptScore W4313339962C168563851 @default.
• W4313339962 hasConceptScore W4313339962C2776694085 @default.
• W4313339962 hasConceptScore W4313339962C2777802072 @default.
• W4313339962 hasConceptScore W4313339962C2778257484 @default.
• W4313339962 hasConceptScore W4313339962C2778715236 @default.
• W4313339962 hasConceptScore W4313339962C2778749236 @default.
• W4313339962 hasConceptScore W4313339962C2780347916 @default.
• W4313339962 hasConceptScore W4313339962C2780886150 @default.
• W4313339962 hasConceptScore W4313339962C71924100 @default.
• W4313339962 hasLocation W43133399621 @default.
• W4313339962 hasLocation W43133399622 @default.
• W4313339962 hasOpenAccess W4313339962 @default.
• W4313339962 hasPrimaryLocation W43133399621 @default.
• W4313339962 hasRelatedWork W2176136391 @default.
• W4313339962 hasRelatedWork W2413823267 @default.
• W4313339962 hasRelatedWork W2551646801 @default.
• W4313339962 hasRelatedWork W2559118752 @default.
• W4313339962 hasRelatedWork W2884705338 @default.
• W4313339962 hasRelatedWork W2989968794 @default.
• W4313339962 hasRelatedWork W2990518684 @default.
• W4313339962 hasRelatedWork W4200217217 @default.
• W4313339962 hasRelatedWork W4308179953 @default.
• W4313339962 hasRelatedWork W4310953841 @default.
• W4313339962 hasVolume "248" @default.
• W4313339962 isParatext "false" @default.
• W4313339962 isRetracted "false" @default.
• W4313339962 workType "article" @default.